Article Figures & Data
Figures
- Figure 1.
The observed proportions of (A) women and (B) men with good, moderate, or no EULAR responses, as well as sample sizes, are shown for each followup. A EULAR response could not be assessed for some patients who were missing DAS28 data at baseline; thus sample sizes are smaller than those shown in Figure 3.
- Figure 2.
Expected probabilities achieving a moderate/good EULAR response over time are shown, as an example, in men versus women in (A) early RA and (B) established RA, using mean baseline values of age, 28-joint Disease Activity Score (DAS28), and RA duration computed for early and established disease — based on the GEE model in Table 2.
- Figure 3.
The observed mean values of the 28-joint Disease Activity Score (DAS28) among men and women in early versus established RA and sample sizes at each followup are shown.
Tables
- Table 1.
Summary of disease characteristics and medications at baseline by rheumatoid arthritis (RA) duration and sex. Results are mean ± SD or medians (interquartile range), unless otherwise indicated.
RA Duration ≤ 2 Years RA Duration > 2 Years Characteristic Men, n = 148 Women, n = 328 p Men, n = 408 Women, n = 1245 p Age at diagnosis, yrs 51.3 ± 13.2 50.1 ± 14.5 0.37 44.6 ± 12.8 43.2 ± 15.0 0.07 Disease duration, yrs 1.23 ± 0.74 1.21 ± 0.70 0.76 13.1 ± 8.9 13.8 ± 10.0 0.18 Radiographic erosions, % 51.9 49.1 0.69 84.2 81.9 0.49 RF seropositivity, % 66.3 58.5 0.20 85.4 81.3 0.18 RA disease activity, % Mild 6.3 2.6 5.7 4.8 Moderate 43.1 43.3 0.16 40.7 38.0 0.43 Severe 50.7 54.1 53.6 57.2 DAS28 5.1 ± 1.2 5.2 ± 1.1 0.45 5.2 ± 1.2 5.3 ± 1.1 0.26 Tender joint count 8 (4–16) 10 (5–16) 0.13 8 (4–14) 9 (5–15) 0.02 Swollen joint count 6 (3–11) 6 (4–10) 0.96 7 (4–11) 7 (4–11) 0.74 CRP 15 (7–45) 11 (5–31) 0.03 18 (8–36) 17 (8–35) 0.11 Patient global score 59.7 ± 21.5 64.1 ± 23.1 0.05 61.1 ± 21.7 62.3 ± 23.0 0.32 Physician global score 48.9 ± 21.7 47.9 ± 20.3 0.65 47.1 ± 21.2 47.4 ± 21.2 0.79 HAQ-DI 1.0 ± 0.7 1.3 ± 0.7 0.0001 1.1 ± 0.8 1.5 ± 0.8 < 0.00005 Pain VAS 55.1 ± 22.7 58.8 ± 23.7 0.12 57.1 ± 21.9 58.1 ± 22.4 0.45 Fatigue VAS 59.3 ± 22.8 68.3 ± 21.2 0.35 47.1 ± 22.3 50.3 ± 25.8 0.60 Smoking history, % Current smoker 42.9 34.3 0.33 43.3 31.8 0.04 Ever smoker 71.4 65.7 0.51 80.4 59.5 < 0.0005 Methotrexate, % 71 65.2 0.22 65.9 65.8 0.96 Prednisolone, % 40.5 35.4 0.28 52.9 40.9 < 0.0005 Anti-TNF therapy, % Infliximab 42.6 43 36.8 40.4 Adalimumab 31.1 31.7 0.97 35.3 34.4 0.37 Etanercept 26.4 25.3 27.9 25.2 -
RF: rheumatoid factor; DAS28: 28-joint Disease Activity Score and C-reactive protein; CRP: C-reactive protein; HAQ-DI: Health Assessment Questionnaire-Disability Index; VAS: visual analog scale; TNF: tumor necrosis factor.
-
- Table 2.
Predictors of a moderate or good European League Against Rheumatism (EULAR) response in early and established rheumatoid arthritis (RA); generalized estimating equations (GEE) model.
Outcome Variable: Moderate/Good EULAR Response RA ≤ 2 Years RA > 2 Years Coefficient (95% CI) p Coefficient (95% CI) p Sex* 0.93 (0.31, 1.55) 0.003 0.02 (−0.32, 0.36) 0.90 Followup, months 0.08 (0.05, 0.12) < 0.0005 0.02 (0.009, 0.04) 0.001 Sex × followup −0.08 (−0.12, − 0.04) < 0.0005 0.003 (−0.01, 0.02) 0.70 Age** −0.01 (−0.02, 0.003) 0.14 −0.002 (−0.01, 0.006) 0.62 RA duration** 0.18 (−0.14, 0.49) 0.27 −0.002 (−0.01, 0.008) 0.70 DAS28** 0.46 (0.25, 0.67) < 0.0005 0.62 (0.52, 0.72) < 0.0005 Anti-TNF therapy** 0.05 (−0.22, 0.32) 0.72 0.18 (0.05, 0.30) 0.006 Methotrexate** 0.76 (0.33, 1.19) 0.001 0.25 (0.05, 0.46) 0.01 Prednisolone** −0.32 (−0.72, 0.08) 0.11 −0.31 (−0.50, −0.12) 0.002 Intercept −2.28 (−3.83, −0.72) 0.004 −2.36 (−3.15, —1.57) < 0.0005
In this issue
